RESEARCH



Maternal gestational diabetes mellitus and the childhood asthma in offspring: a meta-analysis



Xufeng Huang^{1*}, Zhengguo Huang¹, Jing Zhang¹ and You Jiang¹

Abstract

Background Maternal diabetes might be related to a high risk of allergic disease in offspring. However, it remains unknown if maternal gestational diabetes mellitus (GDM) is also associated with a high incidence of childhood asthma in offspring. A systematic review and meta-analysis was performed to investigate the above association.

Methods Relevant observational studies were obtained by search of electronic databases including Medline, Embase, Cochrane Library, and Web of Science. A randomized-effects model was selected to pool the data by incorporating the influence of potential heterogeneity. The Newcastle-Ottawa Scale was used for study quality evaluation. Subgroup analyses were performed to evaluate the potential influences of study characteristics on the outcome.

Results Ten datasets from seven moderate to high quality cohort studies, involving 523,047 mother-child pairs were included in the meta-analysis. Overall, maternal GDM was associated with a higher risk of childhood asthma in offspring (risk ratio [RR]: 1.22, 95% confidence interval [CI]: 1.07 to 1.39, p = 0.003; $I^2 = 30\%$). Subgroup analyses showed that the association was not significantly affected by study design, validation methods for GDM, or diagnostic strategy for asthma (p for subgroup analyses all > 0.05). The association between maternal GDM and asthma in offspring was more remarkable after adjusting maternal body mass index in early pregnancy (RR: 1.50 versus 1.06, p < 0.001), but significantly weakened after adjusting hypertensive disorders during pregnancy (RR: 1.08 versus 1.50, p=0.001).

Conclusions Maternal GDM may be associated with an increased incidence of childhood asthma in offspring. **Keywords** Gestational diabetes mellitus, Asthma, Offspring, Risk factor, Meta-analysis

*Correspondence: Xufeng Huang xfhuang_6982@21cn.com ¹Department of Pediatrics, Fuyang First People's Hospital, No. 429 Beihuan Road, Fuyang District, Hangzhou 311400, China



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Asthma is a chronic and allergic disease which usually starts in childhood. Children with asthma experience respiratory symptoms such as wheezing, coughing, shortness of breath, chest tightness, as well as variable airflow limitation [1, 2]. Accumulating evidence suggests that prevalence of childhood asthma, as well as that of allergic diseases, has risen dramatically from the middle of the 20th century in developed countries, probably due to the changes of environmental exposures and lifestyles [3, 4]. Although children with asthma could be better controlled with standard pharmacological interventions, acute asthma attack may still happen as induced by factors such as respiratory infection. In fact, acute asthma attack has become one of the most common reasons for emergency department visit or hospitalization in children [5, 6]. Accordingly, it is important to identify risk factors for asthma pathogenesis. It has been suggested that a variety of maternal factors may be related to asthma pathogenesis in offspring, such as maternal smoking during pregnancy [7], pre-pregnancy maternal obesity [8], gestational weight gain [9], and gestational hypertensive disorders [10] etc. Besides, it has also been suggested that maternal diabetes may be a risk factor of allergic disease in offspring [11]. However, the potential association between maternal gestational diabetes mellitus (GDM) and the risk of asthma in offspring remains not fully understood [12, 13]. Therefore, in this study, we performed a systematic review and meta-analysis to investigate if maternal GDM is a risk factor of childhood asthma in offspring.

Methods

We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA 2020) [14, 15] and Meta-analysis Of Observational Studies in Epidemiology (MOOSE) [16] guidelines in the conducting and reporting of the meta-analysis.

Selection of eligible studies

The PICOS criteria were used for study inclusion.

(1) P (Participants): Pregnant women;

(2) I (Intervention/exposure): With GDM during pregnancy;

(3) C (Control/comparator): No GDM during pregnancy;

(4) O (Outcome): Incidence of asthma in offspring;

(5) S (Study design): Observational studies, including cross-sectional studies, case-control studies, or cohort studies;

The diagnostic strategies for GDM and asthma were consistent with the methods applied in the original articles. Only studies published as full-length articles were included. Grey literatures, such as abstracts and unpublished data were excluded because these studies were typically not peer-reviewed, and inclusion of these studies may affect the reliability of the meta-analysis results. Reviews, editorials, meta-analyses, preclinical studies, studies that did not evaluate GDM during pregnancy, or studies that did not report the incidence of asthma in offspring were excluded. For studies with overlapped patients, the one with the largest sample size was included for the subsequent meta-analysis.

Search of electronic databases

We identified relevant studies by a systematic search of Medline, Embase, Cochrane Library, and Web of Science electronic databases using the following search strategy: ("gestational diabetes" OR "GDM" OR ("gestational" OR "pregnancy" OR "pregnant") AND ("diabetes" OR "diabetic" OR "hyperglycemia")) AND ("asthma" OR "wheeze" OR "wheezing" OR "pulmonary" OR "lung" OR "allergy" OR "allergic") AND ("child" OR "children" OR "adolescent" OR "pediatric" OR "pediatric" OR "infant" OR "neonate" OR "newborn" OR "toddler"). The search was from the inception of the databases to the date of last search (February 26, 2023). Only clinical studies published in English were selected. According the aim of the meta-analysis, only original studies were included. However, we also performed a manual check-up for the reference lists of the related original and review articles for potential identification of non-included original studies.

Study quality evaluation and data collection

The Newcastle-Ottawa Scale (NOS) [17] was used for study quality assessment, which included three domains such as defining of study groups, between-group comparability, and validation of the outcome. A total of nine criteria were incorporated for the NOS, and one point was given if a certain criterion was met by the individual study. This scale totally scored from 1 to 9 stars, with 9 stars indicating the highest study quality level. Two of the authors independently conducted electronic database search, extraction of study data, and assessment of study quality according to the inclusion criteria described above. If there were discrepancies, discussion with the corresponding author was indicated to resolve them. The extracted data included the following: [1] study information (authors, countries, publication year, and study design); [2] numbers of mother-child pairs included, maternal age at index birth, methods for validation of GDM, and numbers of women with GDM; [3] age of children at the diagnosis of asthma, sex of offspring, methods for validation of asthma in children, numbers of children who developed asthma; and [4] variables included in the multivariate regression analysis for the association between maternal GDM and asthma in offspring.

Statistical methods

Risk ratios (RRs) and 95% confidence intervals (CIs) were selected as the general outcome variable for the relationship between maternal GDM and the incidence of asthma in offspring. For studies that reported odds ratio (OR), data were converted to relative risks (RRs) for the meta-analysis as previously reported [18] (RR=OR/ $([1-pRef]+[pRef\times OR])$, where pRef is the prevalence of the outcome in the reference group (non-GDM group). Data of RRs and standard errors (SEs) were calculated from 95% CIs or P values, and an additional logarithmical transformation was performed to stabilize variance and normalize to the distribution [19]. The Cochrane O test was used to evaluate the heterogeneity, and the I² statistic was also estimated [20]. Heterogeneity was deemed to be significant if $I^2 > 50\%$. We used a randomized-effects model for data synthesis because this model has incorporated the potential between-study heterogeneity and could provide a more generalized result [19]. Sensitivity analyses by excluding one dataset at a time were used to evaluate the stability of the findings. Subgroup analysis was performed to evaluate the association between maternal GDM and asthma in offspring according to study design, methods for validation of GDM and asthma, and adjustment of maternal body mass index (BMI) in early pregnancy or gestational hypertensive disorders. The funnel plots were constructed and a visual inspection of the symmetry was conducted to reflect the publication bias. The Egger's regression asymmetry test was further performed for the evaluation of potential publication bias [21]. We used the RevMan (Version 5.1; Cochrane Collaboration, Oxford, UK) and Stata (version 12.0; Stata Corporation, College Station, TX) software for the statistical analyses.

Results

Results of database search

The database search process is summarized in Fig. 1. Briefly, 722 articles were found in the initial literature search of the databases; after excluding the duplications, 573 studies remained. An additional 552 were excluded through screening of the titles and abstracts mainly because of the irrelevance to the meta-analysis. The remaining 21 studies underwent a full-text review, of which 14 were further excluded for the reasons listed in Fig. 1. Finally, seven observational studies [22–28] were included in the meta-analysis.

Characteristics of the included studies

As shown in Table 1, seven cohort studies, which include two prospective cohorts [22, 23, 25, 27, 28] and five retrospective cohorts [22, 23, 25, 27, 28], were available for the meta-analysis. These studies were published between 2018 and 2023 and performed in Israel, the United States, Canada, China, and Greece, respectively. Overall, 523,047 mother-child pairs were included. The mean maternal age at index birth was 26.0 to 33.1 years. Medical records were reviewed for the validation of GDM in six studies [22-24, 26-28], while interview with questionnaires was used in the other study [25]. Accordingly, 46,286 (8.8%) of them had GDM in during the index pregnancy. As for the included children, they were evaluated for the diagnosis of asthma in 2~18 years, and the proportions of male were 49.8~54.5%. The validation of the diagnosis of asthma in offspring was achieved by review medical records in four studies [22-24, 28], by interview with their parents via questionnaires in two studies [25, 27], and by check the International Classification of Diseases codes of medical databases in another study [26]. A total of 44,683 (8.5%) of children developed asthma. Variables including demographic information of children and their mothers, ethnicity, maternal age at index birth, maternal smoking in pregnancy, and socioeconomic factors etc. were also adjusted to a different degree among the included studies. The NOS of the included studies were all 6~9 stars, suggesting moderate to good quality (Table 2).

Meta-analysis results

Since two studies reported outcomes in women with dietary-treated GDM and pharmacologically treated GDM [22, 23], and another one reported outcome according to the gender of the offspring [26], these datasets were included into the meta-analysis independently. Overall, ten datasets were included. Pooled results showed that maternal GDM was associated with a higher risk of childhood asthma in offspring (RR: 1.22, 95% CI: 1.07 to 1.39, p=0.003; $I^2=30\%$; Fig. 2A). Sensitivity analyses by excluding one dataset at a time showed consistent result (RR: 1.16 to 1.27, p all <0.05). Subgroup analyses showed that the association was not significantly affected by study design (Fig. 2B), validation methods for GDM (Fig. 3A), or diagnostic strategy for asthma (Fig. 3B, p for subgroup analyses all >0.05). Interestingly, subgroup analysis showed that the association between maternal GDM and asthma in offspring was more remarkable in studies with adjustment of maternal BMI in early pregnancy as compared to those without adjustment maternal BMI (RR: 1.50 versus 1.06, p<0.001; Fig. 4A). Moreover, the association was significantly weakened in studies with the adjustment of maternal hypertensive disorders during pregnancy as compared to those without adjustment of this factor (RR: 1.08 versus 1.50, p=0.001; Fig. 4B).

Publication bias

Figure 5 shows the funnel plots regarding the relationship maternal GDM and the risk of childhood asthma in




Fig. 1 Flowchart of database search and study inclusion

offspring. Visual inspection found symmetry of the plots, which suggested a low risk of publication bias. Results of Egger's regression tests also suggested low risk of publication bias (p=0.68).

Discussion

In this meta-analysis, we pooled the results of ten datasets from seven cohort studies and showed that maternal GDM may be associated with a higher risk of childhood asthma in offspring. The results were not significantly changed in sensitivity analysis by excluding one dataset at a time, suggesting the robustness of the finding. In addition, consistent results were obtained in subgroup analyses according to study design, validation methods for GDM, and diagnostic strategy for asthma. Moreover, the association between maternal GDM and the risk of childhood asthma in offspring was more remarkable in studies after adjustment of maternal BMI at early pregnancy, suggesting the association is independent of maternal obesity at pregnancy. Finally, the association was weakened in studies after adjustment of maternal gestational hypertensive disorders, suggesting the association between maternal GDM and the risk of childhood asthma in offspring may partly be confounded by the concurrent maternal gestational hypertensive disorders. Taken together, results of the meta-analysis suggest that maternal GDM may be a risk factor of childhood asthma in offspring.

To the best of our knowledge, few meta-analyses have been performed to investigate the potential influence of maternal GDM on the incidence of childhood asthma in offspring. As far as we know, only one previous metaanalysis evaluated the relationship between maternal diabetes in pregnancy and risk of allergic disease in offspring [11]. This meta-analysis included eight observational studies published before 2019 and showed that maternal

Study	Country	Design	Number of mothers included	Maternal age at index birth	Methods for validation of GDM in	Number of moth- ers with	Number of children evaluated	Age of children at asthma	Male off- spring	Methods for validation of asthma in	No. of children with	Variables adjusted/matched
Zam- stein	Israel	RC	216,197	(years) 28.4	mothers Medical records	GDM 10,184	216,197	diagnosis 11.2 years, at least 4 years	(%) 51	children Medical records	5 ,481	Maternal age, ethnicity, GA, hyperten- sive disorders of pregnancy, maternal
Z016 Mar- tinez 2020	USA	RC	97,554 30.2	30.2	Medical records	9836	97,554	Mean: 7.6 years, at least 5 years	51.4	Medical records	15,123	Birth year, maternal age, parity, educa- Birth year, maternal age, parity, educa- tion, household income, maternal race/ethnicity, history of comorbidity other than diabetes or asthma, history of maternal asthma, smoking during
Nas- reen 2021	Canada	S	19,933 29.2	29.2	Questionnaire	1178	19,933	6∼15 years	50	Questionnaire	1,639	pregnancy, and sex of the child Maternal age at pregnancy, maternal smoking, maternal high blood pressure during pregnancy, multiple gestation, maternal educational attainment, annual household income, urban
Adgent USA 2021	: USA	DG	1,107	26	Medical records	62	1,107	3.7 ~ 6.5 years	49.8	Medical records	173	residency, and sex of the child Maternal age, race, prenatal smoking, pre-pregnancy BMI, parity, asthma history, socioeconomic status, and sex
Dumas 2022	USA	Dd	16,351 30.3	30.3	Medical records	769	16,351	3~5 years	52.1	ICD codes	2,306	or outputting Maternal age at delivery, asthma, ma- ternal race/ethnicity, smoking status, insurance status at birth, mode of
Ma 2023	China	RC	166,772 27.8	27.8	Medical records	24,036	166,772	Mean: 8.6 years, 6~12 years	54.5	Questionnaire	19,722	ucenvery, and carry pregnancy piven Maternal age, educational level, BMI, maternal smoking during pregnancy, single child, family monthly income, children's sex and residential region
Papan- dreou 2023	Greece	КС	5,133 33.1	33.1	Medical records	221	5,133	2~5 years	NR	Medical records	239	

	Representa- tiveness of the exposed cohort	Selection of the non- exposed cohort	Ascer- tain- ment of exposure	Outcome not pres- ent at baseline	Control for ma- ternal age	Control for other con- founding factors	Assess- ment of outcome	Enough Iong follow- up duration		Total
Zamstein 2018	0	1	1	1	1	1	1	1	1	8
Martinez 2020	0	1	1	1	1	1	1	1	1	8
Nasreen 2021	0	1	0	1	1	1	0	1	1	6
Adgent 2021	1	1	1	1	1	1	1	1	1	9
Dumas 2022	1	1	1	1	1	1	0	1	1	8
Ma 2023	0	1	1	1	1	1	0	1	1	7
Papandreou 2023	0	1	1	1	1	1	1	1	1	8

				Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV, Random, 95% CI	IV, Random, 95% CI
amstein 2018 diet	-0.07257069	0.06548976	13.3%	0.93 [0.82, 1.06]	
amstein 2018 pharma	-0.0618754	0.21554928	5.9%	0.94 [0.62, 1.43]	
Aartinez 2020 diet	0	0.04090374	14.4%	1.00 [0.92, 1.08]	+
Aartinez 2020 pharma	0.15700375	0.05206514	13.9%	1.17 [1.06, 1.30]	
lasreen 2021	0.22314355	0.0975895	11.5%	1.25 [1.03, 1.51]	
Adgent 2021	0.69813472	0.22169333	5.7%	2.01 [1.30, 3.10]	
Dumas 2022 boys	0.3435897	0.13078031	9.6%	1.41 [1.09, 1.82]	
Dumas 2022 girls	0.15700375	0.18761468	6.9%	1.17 [0.81, 1.69]	
/a 2023	0.45742485	0.08828899	12.0%	1.58 [1.33, 1.88]	
apandreou 2023	0.35767444	0.19388013	6.7%	1.43 [0.98, 2.09]	
otal (95% CI)			100.0%	1.22 [1.07, 1.39]	•
leterogeneity: Tau ² = 0.0	03; Chi² = 45.19, di	f = 9 (P < 0.00	001); l ² =	80% —	
est for overall effect: Z =		,	,,		0.5 0.7 1 1.5 2
				Risk Ratio	Risk Ratio
Study or Subaroup	log[Risk Ratio]	SE	Weight	IV. Random, 95% CI	IV. Random, 95% CI
.2.1 Prospective			-		
Adgent 2021	0.69813472	0.22169333	5.7%	2.01 [1.30, 3.10]	
Dumas 2022 bovs		0.13078031	9.6%	1.41 [1.09, 1.82]	_
Dumas 2022 girls		0.18761468	6.9%	1.17 [0.81, 1.69]	
Subtotal (95% CI)			22.3%	1.45 [1.12, 1.89]	
leterogeneity: Tau ² = 0.0	02; Chi² = 3.51, df :	= 2 (P = 0.17);	l² = 43%		
est for overall effect: Z =	= 2.78 (P = 0.005)				
.2.2 Retrospective					
Zamstein 2018 diet					
amstein zu to diet	-0.07257069	0.06548976	13.3%	0.93 [0.82, 1.06]	
		0.06548976 0.21554928	13.3% 5.9%	0.93 [0.82, 1.06] 0.94 [0.62, 1.43]	
Zamstein 2018 pharma Martinez 2020 diet	-0.0618754			0.94 [0.62, 1.43]	
Zamstein 2018 pharma Martinez 2020 diet	-0.0618754 0	0.21554928 0.04090374	5.9%	0.94 [0.62, 1.43] 1.00 [0.92, 1.08]	
Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma	-0.0618754 0 0.15700375	0.21554928 0.04090374 0.05206514	5.9% 14.4% 13.9%	0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30]	
Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Nasreen 2021	-0.0618754 0 0.15700375 0.22314355	0.21554928 0.04090374 0.05206514 0.0975895	5.9% 14.4% 13.9% 11.5%	0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 1.25 [1.03, 1.51]	* * *
Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Nasreen 2021 Ma 2023	-0.0618754 0 0.15700375 0.22314355 0.45742485	0.21554928 0.04090374 0.05206514 0.0975895 0.08828899	5.9% 14.4% 13.9% 11.5% 12.0%	0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 1.25 [1.03, 1.51] 1.58 [1.33, 1.88]	* * *
Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Nasreen 2021	-0.0618754 0 0.15700375 0.22314355 0.45742485	0.21554928 0.04090374 0.05206514 0.0975895	5.9% 14.4% 13.9% 11.5%	0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 1.25 [1.03, 1.51]	
amstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Jasreen 2021 Ma 2023 "apandreou 2023 Subtotal (95% CI)	-0.0618754 0 0.15700375 0.22314355 0.45742485 0.35767444	0.21554928 0.04090374 0.05206514 0.0975895 0.08828899 0.19388013	5.9% 14.4% 13.9% 11.5% 12.0% 6.7% 77.7%	0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 1.25 [1.03, 1.51] 1.58 [1.33, 1.88] 1.43 [0.98, 2.09] 1.16 [1.00, 1.33]	* * * *
Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Nasreen 2021 Ma 2023 Papandreou 2023	-0.0618754 0 0.15700375 0.22314355 0.45742485 0.35767444 03; Chi ² = 34.24, dt	0.21554928 0.04090374 0.05206514 0.0975895 0.08828899 0.19388013	5.9% 14.4% 13.9% 11.5% 12.0% 6.7% 77.7%	0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 1.25 [1.03, 1.51] 1.58 [1.33, 1.88] 1.43 [0.98, 2.09] 1.16 [1.00, 1.33]	* * * * *
Zamstein 2018 pharma Aartinez 2020 diet Aartinez 2020 pharma Vasreen 2021 Aa 2023 "apandreou 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0.0	-0.0618754 0 0.15700375 0.22314355 0.45742485 0.35767444 03; Chi ² = 34.24, dt	0.21554928 0.04090374 0.05206514 0.0975895 0.08828899 0.19388013	5.9% 14.4% 13.9% 11.5% 12.0% 6.7% 77.7%	0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 1.25 [1.03, 1.51] 1.58 [1.33, 1.88] 1.43 [0.98, 2.09] 1.16 [1.00, 1.33]	* * * * *
Aanstein 2018 pharma Aartinez 2020 diet Aartinez 2020 pharma Vasreen 2021 Papandreou 2023 Papandreou 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0.0 Test for overall effect: Z =	-0.0618754 0 0.15700375 0.22314355 0.45742485 0.35767444 03; Chi ² = 34.24, dt = 2.00 (P = 0.05)	0.21554928 0.04090374 0.05206514 0.0975895 0.08828899 0.19388013 f = 6 (P < 0.00	5.9% 14.4% 13.9% 11.5% 12.0% 6.7% 77.7% 0001); I ² =	0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 1.25 [1.03, 1.51] 1.58 [1.33, 1.88] 1.43 [0.98, 2.09] 1.16 [1.00, 1.33] 82%	

Fig. 2 Forest plots for the meta-analysis of the association between maternal GDM and childhood asthma in offspring. A, forest plots for the overall metaanalysis; and B, forest plots for the subgroup analysis according to study design

diabetes mellitus may increase the risk of allergic diseases in their children, including asthma. However, studies evaluating maternal pregestational and GDM were both included in this meta-analysis, and for the outcome of childhood asthma, all of the included studies evaluated the influences of preexisting diabetes, rather than GDM [11]. Discrimination maternal pregestational (type 1 or type 2 diabetes) and GDM is important because they may have different pathophysiologic mechanisms [29] and different impacts on maternal and neonatal outcomes [30]. For example, one of the included studies showed that the risk of childhood asthma was predominately observed for exposure to maternal preexisting T2D, while was rater small for GDM [23].

Results of our meta-analysis further validated the hypothesis of the relationship between hyperglycemia in pregnancy and the risk of childhood asthma in offspring, by showing that maternal GDM may also be associated

				Risk Ratio	Risk Ratio
Study or Subgroup	log[Risk Ratio]	SE	Weight	IV. Random, 95% CI	IV. Random, 95% CI
1.3.1 Medical records	<u>loginok natoj</u>	01	Trongine		
Zamstein 2018 diet	-0.07257069	0.06548976	13.3%	0.93 [0.82, 1.06]	
Zamstein 2018 pharma		0.21554928	5.9%	0.94 [0.62, 1.43]	
Martinez 2020 diet		0.04090374	14.4%	1.00 [0.92, 1.08]	+
Martinez 2020 pharma		0.05206514	13.9%	1.17 [1.06, 1.30]	
Adgent 2021	0.69813472	0.22169333	5.7%	2.01 [1.30, 3.10]	
Dumas 2022 boys	0.3435897	0.13078031	9.6%	1.41 [1.09, 1.82]	
Dumas 2022 girls	0.15700375	0.18761468	6.9%	1.17 [0.81, 1.69]	
Ma 2023	0.45742485	0.08828899	12.0%	1.58 [1.33, 1.88]	
Papandreou 2023	0.35767444	0.19388013	6.7%	1.43 [0.98, 2.09]	
Subtotal (95% CI)			88.5%	1.22 [1.05, 1.41]	
Heterogeneity: Tau ² = 0. Test for overall effect: Z		= 8 (P < 0.00	001); l² =	82%	
1.3.2 Questionare					
Nasreen 2021	0.22314355	0.0975895	11.5%	1.25 [1.03, 1.51]	
Subtotal (95% CI)			11.5%	1.25 [1.03, 1.51]	
Heterogeneity: Not appli					
Test for overall effect: Z	= 2.29 (P = 0.02)				
Total (95% CI)			100.0%	1.22 [1.07, 1.39]	•
Heterogeneity: Tau ² = 0.	03; Chi² = 45.19, di	= 9 (P < 0.00	001); l ² =	80%	
		`	<i>,</i> .		0.5 0.7 1 1.5 2
Test for overall effect: Z	= 2.94 (P = 0.003)				
Test for overall effect: Z Test for subaroup differe		if = 1 (P = 0.8	2). I ² = 0%	, 0	
Test for subaroup differe		f = 1 (P = 0.8	2). I² = 0%		Pick Patio
Test for subaroup differe	nces: Chi² = 0.05. d			Risk Ratio	Risk Ratio
Test for subaroup differe Study or Subgroup					Risk Ratio IV. Random. 95% Cl
Test for subaroup differe Study or Subgroup 1.4.1 Medical records	nces: Chi² = 0.05. d	SE	Weight	Risk Ratio IV, Random, 95% Cl	
Test for subaroup differe Study or Subgroup 1.4.1 Medical records Zamstein 2018 diet	nces: Chi ² = 0.05. o log[Risk Ratio] -0.07257069	SE 0.06548976	Weight 13.3%	Risk Ratio <u>IV, Random, 95% Cl</u> 0.93 [0.82, 1.06]	
Test for subaroup differe <u>Study or Subgroup</u> 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma	nces: Chi ² = 0.05. o log[Risk Ratio] -0.07257069 -0.0618754	SE 0.06548976 0.21554928	Weight 13.3% 5.9%	Risk Ratio <u>IV. Random, 95% Cl</u> 0.93 [0.82, 1.06] 0.94 [0.62, 1.43]	
Test for subgroup differe <u>Study or Subgroup</u> 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet	nces: Chi ² = 0.05. (log[Risk Ratio] -0.07257069 -0.0618754 0	SE 0.06548976 0.21554928 0.04090374	Weight 13.3% 5.9% 14.4%	Risk Ratio IV. Random, 95% Cl 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08]	
Test for subgroup differe <u>Study or Subgroup</u> 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma	nces: Chi ² = 0.05. (log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375	SE 0.06548976 0.21554928 0.04090374 0.05206514	Weight 13.3% 5.9% 14.4% 13.9%	Risk Ratio <u>IV. Random. 95% Cl</u> 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30]	
Test for subgroup differe <u>Study or Subgroup</u> 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Adgent 2021	nces: Chi ² = 0.05, o log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375 0.69813472	SE 0.06548976 0.21554928 0.04090374 0.05206514 0.22169333	Weight 13.3% 5.9% 14.4% 13.9% 5.7%	Risk Ratio <u>IV. Random, 95% Cl</u> 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 2.01 [1.30, 3.10]	
Test for subaroup differe Study or Subgroup 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Adgent 2021 Papandreou 2023	nces: Chi ² = 0.05, o log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375 0.69813472	SE 0.06548976 0.21554928 0.04090374 0.05206514	Weight 13.3% 5.9% 14.4% 13.9% 5.7% 6.7%	Risk Ratio <u>IV. Random, 95% CI</u> 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 2.01 [1.30, 3.10] 1.43 [0.98, 2.09]	
Test for subgroup differe <u>Study or Subgroup</u> 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Adgent 2021	nces: Chi ² = 0.05, d log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375 0.69813472 0.35767444 02; Chi ² = 20.56, dl	SE 0.06548976 0.21554928 0.04090374 0.05206514 0.22169333 0.19388013	Weight 13.3% 5.9% 14.4% 13.9% 5.7% 6.7% 59.9%	Risk Ratio <u>IV. Random, 95% Cl</u> 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06 [1.30] 2.01 [1.30, 3.10] 1.43 [0.98, 2.09] 1.11 [0.96, 1.28]	
Test for subgroup differe <u>Study or Subgroup</u> 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Adgent 2021 Papandreou 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0.	nces: Chi ² = 0.05, d log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375 0.69813472 0.35767444 02; Chi ² = 20.56, df = 1.45 (P = 0.15)	SE 0.06548976 0.21554928 0.04090374 0.05206514 0.22169333 0.19388013	Weight 13.3% 5.9% 14.4% 13.9% 5.7% 6.7% 59.9%	Risk Ratio <u>IV. Random, 95% Cl</u> 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06 [1.30] 2.01 [1.30, 3.10] 1.43 [0.98, 2.09] 1.11 [0.96, 1.28]	
Test for subgroup differe Study or Subgroup 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Adgent 2021 Papandreou 2023 Subtotal (95% Cl) Heterogeneity: Tau ² = 0. Test for overall effect: Z	nces: Chi ² = 0.05, d log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375 0.69813472 0.35767444 02; Chi ² = 20.56, df = 1.45 (P = 0.15)	SE 0.06548976 0.21554928 0.04090374 0.05206514 0.22169333 0.19388013	Weight 13.3% 5.9% 14.4% 13.9% 5.7% 6.7% 59.9% 10); I ² = 7	Risk Ratio IV. Random, 95% Cl 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 2.01 [1.30, 3.10] 1.43 [0.98, 2.09] 1.11 [0.96, 1.28] 6%	
Test for suboroup differe <u>Study or Subgroup</u> 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Adgent 2021 Papandreou 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z 1.4.2 Questionare or IC Nasreen 2021	nces: Chi ² = 0.05, d log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375 0.69813472 0.35767444 02; Chi ² = 20.56, df = 1.45 (P = 0.15) D codes 0.22314355	0.06548976 0.21554928 0.04090374 0.05206514 0.22169333 0.19388013 = 5 (P = 0.00	Weight 13.3% 5.9% 14.4% 13.9% 5.7% 6.7% 59.9%	Risk Ratio <u>IV. Random, 95% Cl</u> 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 2.01 [1.30, 3.10] 1.43 [0.98, 2.09] 1.11 [0.96, 1.28] 6%	
Test for subaroup differe <u>Study or Subgroup</u> 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Adgent 2021 Papandreou 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z 1.4.2 Questionare or IC Nasreen 2021 Dumas 2022 boys	nces: Chi ² = 0.05, d log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375 0.69813472 0.35767444 02; Chi ² = 20.56, dl = 1.45 (P = 0.15) D codes 0.22314355 0.3435897	SE 0.06548976 0.21554928 0.04090374 0.05206514 0.22169333 0.19388013 = 5 (P = 0.00 0.0975895 0.13078031	Weight 13.3% 5.9% 14.4% 5.7% 6.7% 59.9% 10); I ² = 7 11.5% 9.6%	Risk Ratio <u>IV. Random, 95% Cl</u> 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 2.01 [1.30, 3.10] 1.43 [0.98, 2.09] 1.11 [0.96, 1.28] 6% 1.25 [1.03, 1.51] 1.41 [1.09, 1.82]	
Test for suboroup differe <u>Study or Subgroup</u> 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Adgent 2021 Papandreou 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z 1.4.2 Questionare or IC Nasreen 2021	nces: Chi ² = 0.05, d log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375 0.69813472 0.35767444 02; Chi ² = 20.56, dl = 1.45 (P = 0.15) D codes 0.22314355 0.3435897 0.15700375	SE 0.06548976 0.21554928 0.04090374 0.05206514 0.22169333 0.19388013 = 5 (P = 0.00 0.0975895 0.13078031 0.18761468	Weight 13.3% 5.9% 14.4% 13.9% 5.7% 6.7% 59.9% 10); I ² = 7 11.5%	Risk Ratio IV. Random, 95% Cl 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 2.01 [1.30, 3.10] 1.43 [0.98, 2.09] 1.11 [0.96, 1.28] 6% 1.25 [1.03, 1.51] 1.41 [1.09, 1.82] 1.17 [0.81, 1.69]	
Test for subgroup differe <u>Study or Subgroup</u> 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Adgent 2021 Papandreou 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z 1.4.2 Questionare or IC Nasreen 2021 Dumas 2022 boys Dumas 2022 girls Ma 2023	nces: Chi ² = 0.05, d log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375 0.69813472 0.35767444 02; Chi ² = 20.56, dl = 1.45 (P = 0.15) D codes 0.22314355 0.3435897 0.15700375	SE 0.06548976 0.21554928 0.04090374 0.05206514 0.22169333 0.19388013 = 5 (P = 0.00 0.0975895 0.13078031	Weight 13.3% 5.9% 14.4% 13.9% 6.7% 59.9% 10); I ² = 7 11.5% 9.6% 6.9% 12.0%	Risk Ratio IV. Random, 95% Cl 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 2.01 [1.30, 3.10] 1.43 [0.98, 2.09] 1.11 [0.96, 1.28] 6% 1.25 [1.03, 1.51] 1.41 [1.09, 1.82] 1.17 [0.81, 1.69] 1.58 [1.33, 1.88]	
Test for subgroup differe <u>Study or Subgroup</u> 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Adgent 2021 Papandreou 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z 1.4.2 Questionare or IC Nasreen 2021 Dumas 2022 boys Dumas 2022 girls	nces: Chi ² = 0.05 d log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375 0.69813472 0.35767444 02; Chi ² = 20.56, dl = 1.45 (P = 0.15) D codes 0.22314355 0.3435897 0.15700375 0.45742485 01; Chi ² = 4.14, df =	SE 0.06548976 0.21554928 0.04090374 0.05206514 0.22169333 0.19388013 = 5 (P = 0.00 0.0975895 0.13078031 0.18761468 0.08828899 = 3 (P = 0.25);	Weight 13.3% 5.9% 14.4% 13.9% 5.7% 6.7% 59.9% 10); 1² = 7 11.5% 9.6% 6.9% 12.0% 40.1%	Risk Ratio IV. Random, 95% Cl 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 2.01 [1.30, 3.10] 1.43 [0.98, 2.09] 1.11 [0.96, 1.28] 6% 1.25 [1.03, 1.51] 1.41 [1.09, 1.82] 1.17 [0.81, 1.69]	
Test for subgroup differe Study or Subgroup 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Adgent 2021 Papandreou 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z 1.4.2 Questionare or IC Nasreen 2021 Dumas 2022 boys Dumas 2022 girls Ma 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z	nces: Chi ² = 0.05 d log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375 0.69813472 0.35767444 02; Chi ² = 20.56, dl = 1.45 (P = 0.15) D codes 0.22314355 0.3435897 0.15700375 0.45742485 01; Chi ² = 4.14, df =	SE 0.06548976 0.21554928 0.04090374 0.05206514 0.22169333 0.19388013 = 5 (P = 0.00 0.0975895 0.13078031 0.18761468 0.08828899 = 3 (P = 0.25);	Weight 13.3% 5.9% 14.4% 13.9% 5.7% 6.7% 59.9% 10); 1² = 7 11.5% 9.6% 6.9% 12.0% 40.1%	Risk Ratio IV. Random, 95% Cl 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 2.01 [1.30, 3.10] 1.43 [0.98, 2.09] 1.11 [0.96, 1.28] 6% 1.25 [1.03, 1.51] 1.41 [1.09, 1.82] 1.71 [0.81, 1.69] 1.58 [1.33, 1.88] 1.38 [1.21, 1.58]	
Test for suboroup differe <u>Study or Subgroup</u> 1.4.1 Medical records Zamstein 2018 diet Zamstein 2018 pharma Martinez 2020 diet Martinez 2020 pharma Adgent 2021 Papandreou 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0. Test for overall effect: Z 1.4.2 Questionare or IC Nasreen 2021 Dumas 2022 boys Dumas 2022 girls Ma 2023 Subtotal (95% CI) Heterogeneity: Tau ² = 0.	nces: Chi ² = 0.05 d log[Risk Ratio] -0.07257069 -0.0618754 0 0.15700375 0.69813472 0.35767444 02; Chi ² = 20.56, df = 1.45 (P = 0.15) D codes 0.22314355 0.3435897 0.15700375 0.45742485 01; Chi ² = 4.14, df = = 4.76 (P < 0.0000)	SE 0.06548976 0.21554928 0.04090374 0.05206514 0.22169333 0.19388013 = 5 (P = 0.000 0.0975895 0.13078031 0.18761468 0.08828899 = 3 (P = 0.25); 1)	Weight 13.3% 5.9% 14.4% 13.9% 5.7% 6.7% 59.9% 10); I ² = 7 11.5% 9.6% 6.9% 12.0% 40.1% I ² = 28% 100.0%	Risk Ratio IV. Random, 95% Cl 0.93 [0.82, 1.06] 0.94 [0.62, 1.43] 1.00 [0.92, 1.08] 1.17 [1.06, 1.30] 2.01 [1.30, 3.10] 1.43 [0.98, 2.09] 1.11 [0.96, 1.28] 6% 1.25 [1.03, 1.51] 1.41 [1.09, 1.82] 1.17 [0.81, 1.69] 1.58 [1.33, 1.88] 1.38 [1.21, 1.58] 1.22 [1.07, 1.39]	

Fig. 3 Forest plots for the subgroup analysis of the association between maternal GDM and childhood asthma in offspring. A, forest plots for the subgroup analysis according to validation methods for GDM; and **B**, forest plots for the subgroup analysis according to diagnostic strategy for asthma in offspring

with childhood asthma. The methodological advantages of the meta-analysis may include the following. Frist, we extensively searched for relevant studies in four commonly used electronic databases, and seven up-to-date cohort studies were retrieved. In addition, only cohort studies were included, which could therefore provide a longitudinal association maternal GDM and childhood asthma in offspring. Moreover, multivariate analyses were used to estimate the association maternal GDM and childhood asthma in offspring in all the included studies, and potential confounding factors such as maternal age, smoking, and social economic factors etc. were adjusted. The results may therefore suggest a potentially independent association between maternal GDM and childhood asthma. At last, to further strengthen the robustness of the findings, multiple sensitivity and subgroup analyses also showed consistent results. Taken together, this metaanalysis confirmed that maternal GDM may be a risk factor of childhood asthma in offspring.

Subgroup analysis showed that the association between maternal GDM and childhood asthma was even stronger in studies after adjustment of maternal BMI in early pregnancy, suggesting the potential association was not confounded by maternal obesity in pregnancy. This is important because pre-pregnancy maternal obesity has been suggested as a possible risk factor for childhood asthma in offspring [9]. Interestingly, subgroup analysis also suggested that the association between maternal GDM and childhood asthma was weakened after adjustment of the prevalence maternal gestational hypertensive




Fig. 4 Forest plots for the subgroup analysis of the association between maternal GDM and childhood asthma in offspring. **A**, forest plots for the subgroup analysis according to adjustment of maternal BMI in early pregnancy; and **B**, forest plots for the subgroup analysis according to adjustment of maternal hypertensive disorder in pregnancy

disorders. These findings may suggest that maternal GDM and gestational hypertensive disorders may share some similar mechanisms which may also be related to the pathogenesis of asthma in offspring, such as inflammatory response of interleukin balance [31] and hormonal changes involving the renin-angiotensin system [32].

This meta-analysis has indicated that GDM could potentially increase the risk of asthma in offspring. Consequently, interventions aimed at preventing GDM may also contribute to the prevention of asthma in the offspring. Various strategies, including lifestyle modifications, dietary supplementation, and pharmacological and non-pharmacological approaches, have been examined as potential means of preventing GDM. Among these interventions, adopting a healthy diet alone, combining a healthy diet with physical activity, supplementing with vitamin B complex, and implementing probiotic treatment have demonstrated promising outcomes in reducing GDM in high-risk women. However, further replication studies are necessary to validate these findings. The initial step in addressing this matter would involve identifying efficacious strategies for preventing GDM, with a particular focus on women who are predisposed to developing GDM. Subsequently, it would be imperative to assess the effectiveness of these measures in mitigating adverse outcomes in offspring, such as asthma.

Currently, the mechanisms underlying the association between GDM and childhood asthma in offspring




Fig. 5 Funnel plots for the publication bias underlying the meta-analysis of the association between maternal GDM and childhood asthma in offspring

remain to be elucidated. A recent preclinical study in a murine model of diet-induced GDM showed that female offspring exposed to GDM displayed increased methacholine reactivity, elevated proinflammatory cytokines in lung lavage, and an elevated abundance of matrix metalloproteinases in their airway, which all subsequently expose them to an increased risk of inflammatory lung conditions, such as asthma [33]. However, these changes were not observed in male offspring exposed to GDM [33]. Although studies are warranted to evaluate the underlying mechanisms and validate the potential offspring gender-specific relationship between exposure to maternal GDM and childhood asthma, this meta-analysis also has clinical implications. Again, these findings support the fetal origin hypothesis of the pathogenesis of asthma. On the other hand, considering that maternal GDM is a common risk factor for multiple poor outcomes in offspring, early monitoring and interventions should be offered to high-risk children of mothers with GDM. In addition, it is also interesting to evaluate whether optimizing the glycemic control of maternal GDM could reduce the risk of asthma in offspring.

This study also has limitations. First, studies available for the meta-analysis are limited, and more prospective cohort studies are needed to validate the finding. At current stage, we are unable to determine if the number of participants included in this meta-analysis is sufficient. Our meta-analysis is based on cohort studies aiming to evaluate if GDM is a risk factor of childhood asthma in offspring, and no intervention was involved. According, trial sequential analysis is not suitable for this metaanalysis because it is usually used for meta-analysis evaluating intervention effect to weigh type I and II errors and to estimate when the effect is large enough to be unaffected by further studies [34]. In addition, in some of the included studies, GDM or asthma in offspring were validated via questionnaire or ICD codes, which may affect the accuracy of the finding. Moreover, although multivariate analysis was used in all of the included studies when the association between maternal GDM and childhood asthma in offspring was estimated, we could not exclude the possibility that there may be residual factors confounding the association, such as maternal vitamin D [35] and fish oil supplementation [36]. Finally, this meta-analysis was on the basis of observational studies. Accordingly, a causative relationship between maternal GDM and childhood asthma in offspring could not be derived based on this meta-analysis.

Conclusion

To sum up, results of the meta-analysis indicate that maternal GDM may be associated with an increased incidence of childhood asthma in offspring. Studies are needed to validate these findings and elucidate the underlying mechanisms. Moreover, studies are needed to determine if optimizing the glycemic control of women with GDM could reduce the incidence of asthma in their offspring.

Abbreviations

BMI	Body mass index;
Cls	Confidence intervals;
GDM	Gestational diabetes mellitus;
NOS	Newcastle–Ottawa Scale;
PRISMA	Preferred Reporting Items for Systematic Reviews and
	Meta-Analyses;

Acknowledgements

Not applicable.

Authors' contribution

XH designed the study. XH and ZH conducted database search, literature review, study quality evaluation, and data collection. XH and JZ performed statistical analyses. XH and YJ interpreted the data and drafted the manuscript. All authors revised the manuscript and approved the submission of the manuscript.

Funding

Not applicable.

Data Availability

All data generated or analyzed during this study are included in this published manuscript.

Declarations

Ethics approval and consent to participate Not Applicable.

Consent for publication

Not Applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 3 May 2023 / Accepted: 14 September 2023 Published online: 15 October 2023

References

- Martin J, Townshend J, Brodlie M. Diagnosis and management of asthma in children. BMJ Paediatr Open. 2022;6(1).
- Castagnoli R, Brambilla I, Giudice MMD, Marseglia GL, Licari A. Applying the new guidelines to asthma management in children. Curr Opin Allergy Clin Immunol. 2023;23(2):132–6.
- von Mutius E, Smits HH. Primary prevention of asthma: from risk and protective factors to targeted strategies for prevention. Lancet. 2020;396(10254):854–66.
- Frey SM, Rowe RK, Halterman JS. The prevalence of childhood asthma: interpreting falling rates in the context of shifting measurement and the COVID-19 pandemic. Curr Opin Pulm Med. 2023;29(3):197–201.
- Saglani S, Fleming L, Sonnappa S, Bush A. Advances in the aetiology, management, and prevention of acute asthma attacks in children. Lancet Child Adolesc Health. 2019;3(5):354–64.
- Pijnenburg MW, Fleming L. Advances in understanding and reducing the burden of severe asthma in children. Lancet Respir Med. 2020;8(10):1032–44.
- Silvestri M, Franchi S, Pistorio A, Petecchia L, Rusconi F. Smoke exposure, wheezing, and asthma development: a systematic review and meta-analysis in unselected birth cohorts. Pediatr Pulmonol. 2015;50(4):353–62.
- Forno E, Young OM, Kumar R, Simhan H, Celedon JC. Maternal obesity in pregnancy, gestational weight gain, and risk of childhood asthma. Pediatrics. 2014;134(2):e535–46.
- 9. Liu S, Zhou B, Wang Y, Wang K, Zhang Z, Niu W. Pre-pregnancy maternal weight and gestational weight gain increase the risk for Childhood Asthma and Wheeze: an updated Meta-analysis. Front Pediatr. 2020;8:134.
- Li P, Xiong T, Hu Y. Hypertensive disorders in pregnancy and risk of asthma in offspring: a systematic review and meta-analysis. BMJ Open. 2021;11(9):e046769.
- Li Z, Yu M, Wang P, Qian H, Fan Y, Li X, et al. Association between maternal diabetes mellitus and allergic diseases in children - a systematic review and meta-analysis. Pediatr Allergy Immunol. 2021;32(5):880–91.

- Dalrymple KV, El-Heis S, Godfrey KM. Maternal weight and gestational diabetes impacts on child health. Curr Opin Clin Nutr Metab Care. 2022;25(3):203–8.
- 13. Rusconi F, Gagliardi L. Pregnancy complications and wheezing and Asthma in Childhood. Am J Respir Crit Care Med. 2018;197(5):580–8.
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
- Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.
- Brooke BS, Schwartz TA, Pawlik TM. MOOSE Reporting Guidelines for Metaanalyses of Observational Studies. JAMA Surg. 2021;156(8):787–8.
- Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2010;http://www.ohri.ca/programs/clinical_epidemiology/ oxford.asp
- 18. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. JAMA. 1998;280(19):1690–1.
- Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. Cochrane Handbook for systematic reviews of interventions version 6.2. The Cochrane Collaboration; 2021. www.training.cochrane.org/handbook
- 20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58.
- 21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.
- Zamstein O, Sheiner E, Wainstock T, Landau D, Walfisch A. Maternal gestational diabetes and long-term respiratory related hospitalizations of the offspring. Diabetes Res Clin Pract. 2018;140:200–7.
- Martinez MP, Lin J, Chow T, Chung J, Wang X, Xiang AH. Maternal gestational diabetes and type 2 diabetes during pregnancy and risk of Childhood Asthma in offspring. J Pediatr. 2020;219:173–9. e1.
- Adgent MA, Gebretsadik T, Reedus J, Graves C, Garrison E, Bush N, et al. Gestational diabetes and childhood asthma in a racially diverse US pregnancy cohort. Pediatr Allergy Immunol. 2021;32(6):1190–6.
- 25. Nasreen S, Wilk P, Mullowney T, Karp I. The effect of gestational diabetes mellitus on the risk of asthma in offspring. Ann Epidemiol. 2021;57:7–13.
- Dumas O, Arroyo AC, Faridi MK, James K, Hsu S, Powe C et al. Cohort study of maternal Gestational Weight Gain, Gestational Diabetes, and Childhood Asthma. Nutrients. 2022;14(23).
- 27. Ma Y, Wu Y, Zhang Y, Jiao T, Guo S, Zhang D et al. Associations between maternal complications during pregnancy and childhood asthma: a retrospective cohort study. ERJ Open Research. 2023:00548–2022.
- Papandreou D, Pavlidou E, Tyrovolas S, Mantzorou M, Andreou E, Psara E et al. Relation of maternal pre-pregnancy factors and Childhood Asthma: a crosssectional survey in Pre-School Children aged 2–5 years old. Med (Kaunas). 2023;59(1).
- Huynh J, Yamada J, Beauharnais C, Wenger JB, Thadhani RI, Wexler D, et al. Type 1, type 2 and gestational diabetes mellitus differentially impact placental pathologic characteristics of uteroplacental malperfusion. Placenta. 2015;36(10):1161–6.
- Wicklow BA, Sellers EAC, Sharma AK, Kroeker K, Nickel NC, Philips-Beck W, et al. Association of Gestational Diabetes and Type 2 diabetes exposure in Utero with the development of type 2 diabetes in First Nations and Non-First Nations offspring. JAMA Pediatr. 2018;172(8):724–31.
- Cao W, Wang X, Chen T, Xu W, Feng F, Zhao S, et al. Maternal lipids, BMI and IL-17/IL-35 imbalance in concurrent gestational diabetes mellitus and preeclampsia. Exp Ther Med. 2018;16(1):427–35.
- 32. Valias GR, Gomes PRL, Amaral FG, Alnuaimi S, Monteiro D, O'Sullivan S, et al. Urinary angiotensinogen-melatonin ratio in Gestational Diabetes and Preeclampsia. Front Mol Biosci. 2022;9:800638.
- Pascoe CD, Basu S, Schwartz J, Fonseca M, Kahnamoui S, Jha A, et al. Maternal diabetes promotes offspring lung dysfunction and inflammation in a sex-dependent manner. Am J Physiol Lung Cell Mol Physiol. 2022;322(3):L373–L84.
- 34. Wetterslev J, Jakobsen JC, Gluud C. Trial Sequential Analysis in systematic reviews with meta-analysis. BMC Med Res Methodol. 2017;17(1):39.
- Wolsk HM, Chawes BL, Litonjua AA, Hollis BW, Waage J, Stokholm J, et al. Prenatal vitamin D supplementation reduces risk of asthma/recurrent wheeze in early childhood: a combined analysis of two randomized controlled trials. PLoS ONE. 2017;12(10):e0186657.

 Wu S, Li C. Influence of maternal Fish Oil supplementation on the risk of asthma or wheeze in children: a Meta-analysis of Randomized controlled trials. Front Pediatr. 2022;10:817110.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.